< 生产厂家价格 >

麦格司他

麦格司他用途

Miglustat(OGT918)是葡萄糖神经酰胺合成酶抑制剂,可作用于I型戈谢病。

点击显示

麦格司他名称

[ CAS 号 ]:
72599-27-0

[ 中文名 ]:
米格鲁他

[ 英文名 ]:
miglustat

[中文别名 ]:

[英文别名 ]:

nojirimycin, N-butyldeoxy-
Butyldeoxynojirimycin
N-Butyldeoxynojirimycin
N-Butyl-deoxynojirimycin
1,5-(BUTYLIMINO)-1,5-DIDEOXY-D-GLUCITOL
N-Butylmoranoline
MFCD00272581
N-(n-Butyl)deoxynojirimycin
BuDNJ
NB-DNJ

麦格司他生物活性

[ 描述 ]:

Miglustat(OGT918)是葡萄糖神经酰胺合成酶抑制剂,可作用于I型戈谢病。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 神经疾病

[参考文献]

[1]. Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7.

[2]. van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82.

[相关活性小分子]

麦格司他物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
394.7±42.0 °C at 760 mmHg

[ 分子式 ]:
C₁₀H₂₁NO₄

[ 分子量 ]:
219.278

[ 闪点 ]:
215.4±26.5 °C

[ 精确质量 ]:
219.147064

[ PSA ]:
84.16000

[ LogP ]:
0.46

[ 蒸汽压 ]:
0.0±2.1 mmHg at 25°C

[ 折射率 ]:
1.546

[ 储存条件 ]:
2-8℃

麦格司他安全信息

[ 个人防护装备 ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ 危险品运输编码 ]:
NONH for all modes of transport

[ 海关编码 ]:
2933399090

麦格司他合成路线

详细合成路线

麦格司他上下游产品

麦格司他上游产品

麦格司他下游产品

麦格司他海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

麦格司他文献

Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.

Antimicrob. Agents Chemother. 53(10) , 4311-9, (2009)

A major obstacle in the treatment of chronic hepatitis C virus (HCV) infection has been the lack of effective, well-tolerated therapeutics. Notably, the recent development of the HCV cell culture infe...

Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses.

Antimicrob. Agents Chemother. 58(6) , 3206-16, (2014)

No antiviral therapies are available for the tick-borne flaviviruses associated with hemorrhagic fevers: Kyasanur Forest disease virus (KFDV), both classical and the Alkhurma hemorrhagic fever virus (...

Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.

J. Virol. 88(21) , 12276-95, (2014)

Hepatitis C virus (HCV) assembles its replication complex on cytosolic membrane vesicles often clustered in a membranous web (MW). During infection, HCV NS5A protein activates PI4KIIIα enzyme, causing...

更多文献